These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 33545056)

  • 1. Decoding the function of an oncogenic transcription factor: finding the first responders.
    Lu C
    Mol Cell; 2021 Feb; 81(3):418-420. PubMed ID: 33545056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Co-existence of AML1-ETO and BCR-ABL1 fusion genes in acute myeloid leukemia: a case report].
    Yao YQ; Jia X; Liu H; Lu QS; Xiong WJ; Zhang Y; Liu QF; Shi PC
    Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):203-206. PubMed ID: 38326048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.
    Xu D; Yang Y; Yin Z; Tu S; Nie D; Li Y; Huang Z; Sun Q; Huang C; Nie X; Yao Z; Shi P; Zhang Y; Jiang X; Liu Q; Yu G
    Blood Cancer J; 2023 Nov; 13(1):168. PubMed ID: 37957175
    [No Abstract]   [Full Text] [Related]  

  • 4. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
    Trinh BQ; Ummarino S; Zhang Y; Ebralidze AK; Bassal MA; Nguyen TM; Heller G; Coffey R; Tenen DE; van der Kouwe E; Fabiani E; Gurnari C; Wu CS; Angarica VE; Yang H; Chen S; Zhang H; Thurm AR; Marchi F; Levantini E; Staber PB; Zhang P; Voso MT; Pandolfi PP; Kobayashi SS; Chai L; Di Ruscio A; Tenen DG
    Blood; 2021 Oct; 138(15):1331-1344. PubMed ID: 33971010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The study of clinical characteristics and prognosis of RUNX1-RUNX1T1 positive acute myeloid leukemia based on next-generation sequencing].
    Wang YL; Gao SJ; Su L; Liu YJ; Zhang YW; Du YZ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):851-854. PubMed ID: 38049338
    [No Abstract]   [Full Text] [Related]  

  • 6. Olaparib combined with low-dose chemotherapy for relapsed
    Lin L; Xue S; Chen J; Gu C; Zhang J; Xing E; Wang W; Wang L; Zhang Z
    Leuk Lymphoma; 2024 Aug; 65(8):1181-1185. PubMed ID: 39041737
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased expression of RUNX3 inhibits normal human myeloid development.
    Menezes AC; Jones R; Shrestha A; Nicholson R; Leckenby A; Azevedo A; Davies S; Baker S; Gilkes AF; Darley RL; Tonks A
    Leukemia; 2022 Jul; 36(7):1769-1780. PubMed ID: 35490198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia.
    Mandell JD; Fisk JN; Cyrenne E; Xu ML; Cannataro VL; Townsend JP
    Leukemia; 2022 Dec; 36(12):2931-2933. PubMed ID: 36369483
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia.
    Zeisig BB; Fung TK; Zarowiecki M; Tsai CT; Luo H; Stanojevic B; Lynn C; Leung AYH; Zuna J; Zaliova M; Bornhauser M; von Bonin M; Lenhard B; Huang S; Mufti GJ; So CWE
    Sci Transl Med; 2021 Feb; 13(582):. PubMed ID: 33627486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interrogation of DNA damage response variants with base editing screens.
    Cuella-Martin R; Hayward SB; Fan X; Chen X; Huang JW; Taglialatela A; Leuzzi G; Zhao J; Rabadan R; Lu C; Shen Y; Ciccia A
    Cell; 2021 Feb; 184(4):1081-1097.e19. PubMed ID: 33606978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy.
    Chen R; Okeyo-Owuor T; Patel RM; Casey EB; Cluster AS; Yang W; Magee JA
    Cell Rep; 2021 Feb; 34(7):108751. PubMed ID: 33596429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.
    Wang T; Pine AR; Kotini AG; Yuan H; Zamparo L; Starczynowski DT; Leslie C; Papapetrou EP
    Cell Stem Cell; 2021 Jun; 28(6):1074-1089.e7. PubMed ID: 33571445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
    Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
    Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML.
    Heimbruch KE; Meyer AE; Agrawal P; Viny AD; Rao S
    Neoplasia; 2021 Mar; 23(3):337-347. PubMed ID: 33621854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
    Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
    Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells.
    Saulle E; Spinello I; Quaranta MT; Pasquini L; Pelosi E; Iorio E; Castelli G; Chirico M; Pisanu ME; Ottone T; Voso MT; Testa U; Labbaye C
    Front Oncol; 2020; 10():621458. PubMed ID: 33614502
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Naseem S; Binota J; Varma N; Virk H; Varma S; Malhotra P
    Int J Hematol Oncol Stem Cell Res; 2021 Jan; 15(1):15-26. PubMed ID: 33613897
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.
    Ianevski A; Lahtela J; Javarappa KK; Sergeev P; Ghimire BR; Gautam P; Vähä-Koskela M; Turunen L; Linnavirta N; Kuusanmäki H; Kontro M; Porkka K; Heckman CA; Mattila P; Wennerberg K; Giri AK; Aittokallio T
    Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33608276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
    Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
    Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
    Front Immunol; 2020; 11():586168. PubMed ID: 33584651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.